BCL11A Control-Sequence Editing for Hemoglobinopathy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemoglobinopathies, such as β-thalassemias and sickle cell anemia, are limited and there is a need for safe and effective therapies to address the genetic basis of these disorders.
Innovation Solution
Utilizing genome engineering tools to create permanent changes in the genome by deleting, modulating, or inactivating the transcriptional control sequence of the BCL11A gene, specifically through methods involving DNA endonucleases to introduce single-strand or double-strand breaks, followed by homology-directed repair or non-homologous end joining, to regulate fetal hemoglobin expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genome engineering tools are used to delete or modulate the BCL11A gene transcriptional control sequence, then fetal hemoglobin production is increased and oxygen transport is improved, but the complexity of the treatment and risk of off-target effects increase
Solution Approach 1:
The patent uses guide RNA molecules as intermediaries to direct DNA endonucleases to specific target sequences in the BCL11A gene. This mediator approach allows precise targeting of the transcriptional control sequence while minimizing off-target effects, resolving the contradiction between treatment effectiveness and safety/complexity
Solution Approach 2:
The treatment approach segments the genome editing process into distinct components: (1) delivery of DNA endonuclease and guide RNA to target cells, (2) specific cleavage of the BCL11A transcriptional control sequence, and (3) natural cellular repair mechanisms that result in gene modulation. This segmentation allows for controlled, stepwise implementation that reduces overall treatment complexity while maintaining effectiveness
2Duration of action of stationary object
If DNA endonucleases are introduced to create permanent genomic changes, then the treatment provides long-lasting effects, but the risk of unwanted side effects and disruption of normal gene regulation increases
Solution Approach 1:
The guide RNA molecules are designed with sequences that are highly specific to the target BCL11A transcriptional control sequence, ensuring that DNA endonucleases act only at the intended genomic location. This local specificity allows permanent therapeutic effects while minimizing disruption to other genes and regulatory elements, thus reducing off-target effects
Solution Approach 2:
The patent employs carefully designed guide RNA sequences that provide feedback control by only directing endonuclease activity to the precise target sequence. The specificity of RNA-DNA hybridization acts as a feedback mechanism that prevents erroneous cleavage, allowing long-lasting therapeutic effects without excessive off-target activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach can ameliorate the effects of hemoglobinopathies by increasing fetal hemoglobin production, thereby improving oxygen transport and reducing symptoms associated with these conditions.
Implementation Method 1
methods involving DNA endonucleases to introduce single-strand or double-strand breaks
Implementation Method 2
followed by homology-directed repair or non-homologous end joining
Implementation Method 3
followed by homology-directed repair or non-homologous end joining
Data Source
AI summary
Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.